SHREE PHARMA: GLP-1 import refusal records

Has FDA refused imports of GLP-1 products from SHREE PHARMA?

Yes. FDA’s import refusal records list 4 refused shipment lines declared as made by SHREE PHARMA (India) whose FDA product code names tirzepatide, from Aug 28, 2024 to Jan 9, 2026. None of them carries a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.

Country
India
City in FDA records
Nagpur
FEI numbers on the lines
3030292324, 3037128949, 3030684763
Refused lines
4
Lines with an Import Alert 66-80 API or powder code
0
Drugs named in the product codes
Tirzepatide
Refusal dates
Aug 28, 2024 to Jan 9, 2026

The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.

Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether SHREE PHARMA is on it.

Refused shipment lines

FDA refusal chargesShipment ID
Jan 9, 2026India61PCY74 TIRZEPATIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).799-1366861-5/10003/1
Jan 2, 2026India61PCY74 TIRZEPATIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).799-9285125-5/10003/1
Jun 17, 2025India61PDP74 TIRZEPATIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).SCS-0867693-9/12/1
Aug 28, 2024India61PCP74 TIRZEPATIDE (ANTI-DIABETIC)Code not listed on Import Alert 66-80UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).SCS-5793865-0/11/1

FDA refusal charges on these lines

A line can carry several charges. Text is FDA’s charge statement, verbatim.

UNAPPROVED: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).4

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.

4 lines from FDA files read Nov 15, 2026.